PYC Therapeutics

Former IKEA franchise owner Alan Tribe has taken charge at local biotech firm Phylogica, lifting his stake to 20 per cent and becoming chairman on the same day chief executive Stephanie Unwin was replaced by Rohan Hockings.

Phylogica has a new chief executive who is determined to bring the Perth biotech’s commercialisation strategy to fruition.

Perth-based medicinal cannabis specialist Zelda Therapeutics has appointed former Phylogica and PharmAust chief executive Richard Hopkins as its managing director.

Shares in biomedical technology business Phylogica were up 13 per cent today after the company announced it had completed a $9.1 million recapitalisation.

Perth biotech Phylogica today announced positive test results from its drug delivery technology, but the news was not enough to sustain a rally in the company's shares, which have risen 33 per cent over the past week.

Phylogica has announced a commercial collaboration with Lions Eye Institute trading under the name Vision Pharma, bringing the biotechnology company a step closer to commercialising its drug delivery technology.

Biotech company Phylogica has announced plans to raise $26.8 million through a rights issue, fully underwritten by chairman and major shareholder Alan Tribe, with the proceeds used primarily to fund preclinicial studies for its leading drug molecule.

Biotech company Phylogica announced it had increased its shareholding in Vision Pharma to 90 per cent, following a $15 million investment using funds it had raised through a recent rights issue.

The ASX has launched a technology index with 46 constituent companies and while several, such as Nearmap and ResApp Health, have a WA connection, none are based in Perth.

Biotech company PYC Therapeutics has sought funding for its lead drug development program that aims to treat childhood blindness.

The updated WA ‘rich list’ shows the state’s iron ore magnates are moving far ahead of people who made their money in other industries.

The rising fortunes of biotech company PYC Therapeutics have bolstered the wealth of its major shareholders, most notably chairman Alan Tribe.

Four companies including VeinTech and Vision Pharma have been selected as finalists in the Great for the State category at the Innovator of the Year Awards.

The recent $100 million sale of Agworld is a badge of success for WA tech but also reveals the sector’s limitations.

A company targeting treatment of blindness was announced as the WA Innovator of the Year on Wednesday night.

The developer is seeking community input before submitting its plans for the vacant site.

GenusPlus Group managing director David Riches was named First Amongst Equals at the 2022 40under40 Awards, ahead of a diverse cohort of Western Australia’s young business leaders.

40under40: The journey from an idea to an approved medication is as difficult as putting a person on the moon, Rohan Hockings says.

Property developer Exal Group has bought a 31,100 square metre lot from a Chinese real estate group, as it progresses its plans for its project worth more than $500 million at the site.

The commercial side of life sciences may have reached a critical mass in WA.

Nedlands-based biotechnology company PYC Therapeutics has raised $30 million to progress its series of drug trials.

Perth biotechnology company PYC Therapeutics will collaborate with Google to develop and host an artificial intelligence platform for precision medicines.

PYC Therapeutics is rattling the tin for up to $74.6 million to fund the progress of its medical drug trials, including for blinding eye and polycystic kidney diseases.

Perth biotech company PYC Therapeutics has hit a major milestone in the development of a first-in-class drug to treat a rare eye disease, recently receiving orphan drug designation from the US FDA.

Business News has significantly overhauled the BN30 index, a proxy for the WA economy, with seven new additions, prompted by the exit of takeover targets MMA Offshore, APM and Decmil.

Perth biotech company PYC Therapeutics has hit another major milestone, gaining approval to move its first-in-class PYC-001 drug to human trials.

Nedlands-based biotech company PYC Therapeutics has received approvals to start human trials over a drug candidate for kidney disease.

Nedlands-based biotech company PYC Therapeutics is rattling the tin for up to $146 million to fund the progression of four novel drug candidates.